Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ImmunoRad: Nelfinavir, Immunotherapy, and Radiation in Advanced Melanoma, Lung, and Kidney Cancer
NCT03050060Phase 2Terminated
- Sponsor
- University of Washington
- Start
- Jun 2017
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nelfinavir in melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), sponsored by University of Washington. Started Jun 2017; status: terminated.
02
Drugs
nelfinavir
03
Conditions
melanomanon-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03050060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03050060.